NCT05824156 - CM-101 in NASH Patients - The SPLASH Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

August 15, 2022

Study Completion Date

August 25, 2022

Conditions

Nonalcoholic Steatohepatitis

Interventions

BIOLOGICAL

5 mg/kg CM-101

CM-101, Monoclonal Ab blocking CCL24

OTHER

Placebo

Trial Locations (9)

Hadassah Ein Kereme - site 201, Jerusalem

Soroka Medical Center - site 203, Beersheba

Carmel Medical Center - site 207, Haifa

Rambam Medical Center - site 202, Haifa

Shaare Zedek Medical Center - site 208, Jerusalem

Galilee Medical Center - site 204, Nahariya

Holy Family Nazareth Hospital - site 206, Nazareth

Rabin Medical Center - site 205, Petah Tikva

The Haim Sheba Medical Center - site 209, Ramat Gan

All Listed Sponsors

lead

ChemomAb Ltd.

INDUSTRY